Brochure
19 Jul 2023
Ashland Pharma Overview
PDF 2.8 MB
Ashland offers a range of excipients and technologies, polymer expertise, and technical support for oral solids, liquids, and parenteral dosage forms. Our solutions include controlled release, binders, disintegrants, solubles, stabilizers, rheology modifiers, and resorbable polymers.
Content provided by our supplier
Ashland Industries Europe GmbH
-
CH
-
2015On CPHI since
-
1000 - 4999Employees
Company types
Other Content from Ashland Industries Europe GmbH (6)
-
News Ashland injectable pharmaceutical excipient accepted into FDA Novel Excipient Review Pilot Program
WILMINGTON, Del., Oct. 31, 2022 (GLOBE NEWSWIRE) announced the United States Food and Drug Administration (FDA) Center for Drug Evaluation and Research Office of New Drugs has accepted Ashland Viatel™ bioresorbable mPEG-PDLLA pharmaceutical excipient in the review cycle of the FDA Novel Excipient Review Pilot Program. -
Video Rapid Response to the European Food Safety Authority (EFSA) Ban on TiO2 as a Food Additive as it Relates to Film Coatings
This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. The session discusses: Challenges faced when removing TiO2 from film coatings Aquarius TM TF. A reliable and effective alternative to TiO2 in film coatings Improved process economics with Aquarius Genesis TF high-solids TiO2-free film coating -
News Ashland announces Klucel™ xtend HPC matrix former for extended-release tablets
Wilmington, Del., Oct. 3, 2022 - Ashland is introducing Klucel™ xtend hydroxypropyl cellulose (HPC) controlled release matrix former, designed to deliver unsurpassed process versatility and release profile efficiency.
Until now, there were limited options for managing the release profile of formulations, especially high dose, controlled release formulations. Ashland’s step change klucel™ xtend HPC has been shown to match the release profile of hypromellose controlled-release formulations at half the polymer concentration. The highly reduced polymer concentration achievable with klucel™ xtend HPC offers the possibility of smaller pills or higher dosage, if necessary. This new excipient offers unrivaled versatility across a broad range of APIs in every manufacturing process: dry granulation, wet-granulation, direct compression, and holt-melt extrusion.
-
Video Excipient Engineering and Design to Improve Processing of Oral Controlled Release Formulations
Hydrophilic polymer matrix systems are widely used in oral controlled drug delivery because of their flexibility to obtain a desirable drug release profile, cost effectiveness, and broad regulatory acceptance.
Hydroxypropyl methyl cellulose (HPMC) is the key matrix former used in the majority of formulations. As controlled release formulations continue to evolve, so does the need for more robust and flexible matrix forming polymers. Join this learning lab session to:
understand key mechanistic aspects of hypromellose-enabled hydrophilic matrix tablets discover how polymer engineering results in optimized Benecel HPMC grades (new Benecel XR & XRF HPMC grades) learn about the advantages of Benecel DC Hypromellose in flow and loss-in-weight (LIW) feeding for continuous manufacturing compared to regular HPMC grades
Click here to register
-
News Ashland announces Polyplasdone™ Plus multifunctional disintegrant for improved pharmaceutical process throughput
Wilmington, Del., June 20, 2023 - Ashland is introducing Polyplasdone™ Plus, a co-processed multifunctional direct compression superdisintegrant containing a glidant and lubricant. Saving time and simplifying development, the multifunctional disintegrant offers superior powder flow and lubrication during pharmaceutical manufacturing. This innovative product eliminates two manufacturing steps and simplifies equipment setup while simultaneously delivering improved tablet hardness and helping ensure the production of consistent, high-quality products in batch and continuous manufacturing. -
News Ashland launches 2021 Environment, Social, and Governance Report
Ashland has raised the bar on its business-driven environment, social and governance (ESG) targets by demonstrating a clear link between its long-range strategic plans and detailed ESG progress.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance